TORONTO and GLIL YAM,
Israel, March 20, 2024 /PRNewswire/ -- IM Cannabis Corp.
(CSE: IMCC) (NASDAQ: IMCC) (the "Company",
"IMCannabis", or "IMC"), a leading medical cannabis
company with operations in Israel
and Germany, will report
operational and financial results for the fourth quarter and full
year 2023 ended December 31, 2023, on
Thursday, March 28, 2024 before the
market opens.
The Company will host a zoom web conference on the same day at
9:00a.m. ET to discuss the results,
followed by a question-and-answer session for the investment
community. Investors are invited to register by clicking here. All
relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will
be available on our website at https://investors.imcannabis.com
within 24 hours after the call.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis
company that provides premium cannabis products to medical patients
in Israel and Germany, two of the largest medical cannabis
markets. The Company has recently exited operations in Canada to pivot its focus and resources to
achieve sustainable and profitable growth in its highest value
markets, Israel and Germany. The Company leverages a transnational
ecosystem powered by a unique data-driven approach and a globally
sourced product supply chain. With an unwavering commitment to
responsible growth and compliance with the strictest regulatory
environments, the Company strives to amplify its commercial and
brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship
with Focus Medical Herbs Ltd., which imports and distributes
cannabis to medical patients, leveraging years of proprietary data
and patient insights. The Company also operates medical cannabis
retail pharmacies, online platforms, distribution centers, and
logistical hubs in Israel that
enable the safe delivery and quality control of IMC products
throughout the entire value chain. In Germany, the IMC ecosystem operates through
Adjupharm GmbH, where it distributes cannabis to pharmacies for
medical cannabis patients. Until recently, the Company also
actively operated in Canada
through Trichome Financial Corp and its wholly owned subsidiaries,
where it cultivated, processed, packaged, and sold premium and
ultra-premium cannabis at its own facilities under the WAGNERS and
Highland Grow brands for the adult-use market in Canada. The Company has exited operations in
Canada and considers these
operations discontinued.
Company Contact:
Anna Taranko, Director Investor
& Public Relations
IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de
Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com
Logo -
https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/im-cannabis-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thursday-march-28-at-900am-et-302094369.html